T2DM and cancer, leading global causes of death , exhibit a notable association in females. This research purposed to assess the incidence of T2DM in woman cancer and to explore the common risk factors between these two common diseases.
Methods: This study conducted a retrospective analysis of adult females' medical records admitted to the Oncology unit within the Internal Medicine Department. The data encompassed 532 women diagnosed with breast, uterine, or ovarian cancer between June 2020 and June 2022. Women were divided into two groups: diabetic and non-diabetic. For each woman, data on age, BMI, medical history (including DM, HTN, IHD, etc.), as well as laboratory and imaging results, was collected.
Results: Breast cancer was detected in 48.1% of cases, uterine cancer in 25.6%, and ovarian cancer in 26.3%. The incidence of breast and uterine cancer was higher during the 6th decade of life for both diabetic and non-diabetics. Breast, uterine, and ovarian cancer occurrence was significantly greater between diabetic and obese patients. In the breast cancer group, the incidence of hypertension and high creatinine levels, both associated with diabetes, was higher than in the non-diabetics . In uterine cancer patients, non-diabetics had a significantly higher IHD incidence than diabetics. Among ovarian cancer patients, diabetic status was related to a greater IHD incidence.
Conclusion: Females with cancer breast, uterus or ovary have higher incidence of T2DM. Postmenopausal cancerous women are at elevated risk of developing T2DM and should undergo timely screening for this condition